Meropenem and Haematotoxicity - a phase IV clinical study of FDA data

Summary:

Haematotoxicity is reported as a side effect among people who take Meropenem (meropenem), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Spironolactone, and have Fever.

The phase IV clinical study analyzes which people have Haematotoxicity when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Haematotoxicity?

Haematotoxicity (toxins that destroy red blood cells) is found to be associated with 343 drugs and 830 conditions by eHealthMe. Check the latest studies of Haematotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

33,250 people reported to have side effects when taking Meropenem.
Among them, 12 people (0.04%) have Haematotoxicity.

Among these 12 people:

How long have people been on Meropenem when they have Haematotoxicity? *

What is the gender of people who have Haematotoxicity when taking Meropenem? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Haematotoxicity when taking Meropenem? *

What are other drugs people take besides Meropenem? *

What are other side effects people have besides Haematotoxicity? *

Fever: 4 people, 33.33%
Thrombocytopenia (decrease of platelets in blood): 2 people, 16.67%
Generalised Oedema (swelling all over the body): 2 people, 16.67%
Bone Marrow Failure: 2 people, 16.67%
Diarrhea: 2 people, 16.67%
Febrile Neutropenia (fever with reduced white blood cells): 2 people, 16.67%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 8.33%
Anuria (failure of the kidneys to produce urine): 1 person, 8.33%
Ascites (accumulation of fluid in the abdominal cavity): 1 person, 8.33%
Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 1 person, 8.33%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 2 people, 16.67%
Fever: 2 people, 16.67%
Shock Haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding): 1 person, 8.33%
Gastric Disorder (disease of stomach): 1 person, 8.33%
Abdominal Pain: 1 person, 8.33%
Abscess (pus): 1 person, 8.33%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 8.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 8.33%
Anaemia (lack of blood): 1 person, 8.33%
Brain Abscess: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and have Haematotoxicity?

- Check whether Haematotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meropenem:

Meropenem (33,295 reports)

Haematotoxicity treatments and more:

Haematotoxicity (8,984 reports)

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematotoxicity:

Haematotoxicity (343 drugs)

Browse all the conditions that are associated with Haematotoxicity:

Haematotoxicity (830 conditions)

Related publications that referenced our studies

Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.